Israel
MDClone is a healthcare data exploration platform company that helps organizations harness the power of medical data to improve patient health and clinical outcomes. Headquartered in Israel and with locations in the US, MDClone has forged strategic partnerships with major health systems, government entities, payors, and life sciences companies across the globe. A wide variety of health experts, from physicians to regulators, including the United States Food and Drug Administration (FDA), use its platform.
Building a secure platform capable of unlocking complex scientific insights
Healthcare and life sciences organizations have access to huge volumes of data from various sources, often stored in different locations and formats. This medical data is laced with technical terminology that requires a high level of scientific expertise and context to understand and analyze effectively. General-purpose analytics tools and AI models cannot answer complex questions about topics such as drug delivery, or disease pathways, or accurately model treatment plans. Even clinicians, who are experts in their field, typically lack the data science expertise to unlock actionable insights from data.
At the same time, protecting patient data is paramount. Operating within a tightly regulated sector, healthcare and pharmaceutical organizations must comply with stringent, region-specific privacy regulations. To empower clinical teams and researchers to access, analyze, and act on health data at scale, MDClone built the ADAMS Platform, a self-service healthcare data exploration environment, powered by Cloudera.
"By simplifying data pipelines and standardizing formats, Cloudera has enabled us to create an environment that can efficiently analyze millions of healthcare data points, all underpinned by robust governance features," comments Luz Erez, Co-founder and CTO, MDClone.
Giving MDClone’s clients a flexible, secure data lake
Using Cloudera, MDClone created an open data lake that enables its customers to query information on millions of patients and their medical history to accurately answer critical health questions. The scalability offered by Cloudera supports MDClone’s customers as they grow, as ADAMS is capable of managing the records of up to 20 million patients per client. These records include genetic data, electronic health records, medication information, test results, insights into hospital admissions, and emergency services usage.
With Cloudera, MDClone now has a flexible environment that can be deployed across any infrastructure, whether customers are multi-cloud, hybrid, or on-premises environments. Since MDClone has customers across the US, Europe, and Africa, this flexibility is vital for adhering to evolving local regulations around patient data management. Compliance is further supported by Cloudera’s Shared Data Experience (SDX), which provides integrated and consistent security and agile governance. SDX grants confidence that access to patient records is always authorized, tracked, and audited.
“Cloudera’s hybrid cloud capabilities helps MDClone to fit seamlessly into any environment with trust in the security of the data. This means we’re able to bring our life-changing platform to a wide range of research organizations and healthcare providers,” continues Erez.
AI-driven answers improve patient care and deliver tens of millions in savings
Cloudera manages consistent data formats and pipelines, integrating 15-20TB of medical information into a user-friendly platform. This enables clinicians and scientists to seamlessly extract valuable insights from an ever-growing volume of data. Many technical aspects such as classifying new records are now automated, which minimizes duplicated information and errors.
MDClone now also has a solid data foundation for AI. Cloudera’s support of open standards allows a range of analytics tools to be employed to scrutinize health data, which allows clinicians and researchers to quickly query data to improve patient outcomes in real-time. For example, by analyzing historical records of what drug combinations patients are taking and cross-referencing with reported side effects, the platform can predict whether a new patient is likely to experience any negative drug to drug reactions.
The ADAMS platform also supports longitudinal scientific research studies, which analyze trends over time, including how changing health strategies can unlock cost savings. One hospital used the platform to compare the long-term costs of early detection and treatment versus delayed diagnosis and long term-care for blood clots in the lungs. This involved comparing costs of scans, hospital stay, staffing, medication, and more. The data showed that by shifting to a preventative approach, the hospital could unlock savings of more than $24 million with reduced hospitalizations for patients.
“With Cloudera, we've developed an open platform for healthcare teams rather than programmers, putting data at the fingertips of physicians and researchers all over the world. Cloudera supports our mission to create safer, more cost-effective healthcare environments,” concludes Erez
